TWI843040B - 抗N3pGlu類澱粉β抗體及其用途 - Google Patents

抗N3pGlu類澱粉β抗體及其用途 Download PDF

Info

Publication number
TWI843040B
TWI843040B TW111101008A TW111101008A TWI843040B TW I843040 B TWI843040 B TW I843040B TW 111101008 A TW111101008 A TW 111101008A TW 111101008 A TW111101008 A TW 111101008A TW I843040 B TWI843040 B TW I843040B
Authority
TW
Taiwan
Prior art keywords
antibody
weeks
n3pglu
brain
administered
Prior art date
Application number
TW111101008A
Other languages
English (en)
Chinese (zh)
Other versions
TW202243690A (zh
Inventor
亞當 Ｓ 費雷雪
馬克 明通
約翰 蘭德爾 二世 希姆斯
裘大衛 史帕斯
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202243690A publication Critical patent/TW202243690A/zh
Application granted granted Critical
Publication of TWI843040B publication Critical patent/TWI843040B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111101008A 2021-01-11 2022-01-10 抗N3pGlu類澱粉β抗體及其用途 TWI843040B (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US202163135932P 2021-01-11 2021-01-11
US63/135,932 2021-01-11
US202163155029P 2021-03-01 2021-03-01
US63/155,029 2021-03-01
US202163160380P 2021-03-12 2021-03-12
US63/160,380 2021-03-12
US202163192262P 2021-05-24 2021-05-24
US63/192,262 2021-05-24
US202163227054P 2021-07-29 2021-07-29
US63/227,054 2021-07-29
US202163277298P 2021-11-09 2021-11-09
US63/277,298 2021-11-09
US202163284248P 2021-11-30 2021-11-30
US63/284,248 2021-11-30
US202263296694P 2022-01-05 2022-01-05
US63/296,694 2022-01-05

Publications (2)

Publication Number Publication Date
TW202243690A TW202243690A (zh) 2022-11-16
TWI843040B true TWI843040B (zh) 2024-05-21

Family

ID=80123357

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111101008A TWI843040B (zh) 2021-01-11 2022-01-10 抗N3pGlu類澱粉β抗體及其用途

Country Status (15)

Country Link
US (1) US20240010713A1 (https=)
EP (1) EP4274611A1 (https=)
JP (2) JP7676556B2 (https=)
KR (2) KR20260047659A (https=)
AU (1) AU2022206461B2 (https=)
CA (1) CA3204444A1 (https=)
CL (1) CL2023001992A1 (https=)
CO (1) CO2023009089A2 (https=)
EC (1) ECSP23051813A (https=)
IL (1) IL304072A (https=)
MX (1) MX2023008196A (https=)
PE (1) PE20231748A1 (https=)
TW (1) TWI843040B (https=)
WO (1) WO2022150735A1 (https=)
ZA (1) ZA202306180B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022307687A1 (en) * 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
CA3243602A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
KR20250107906A (ko) * 2022-11-17 2025-07-14 일라이 릴리 앤드 캄파니 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
KR20250173598A (ko) * 2023-03-16 2025-12-10 알즈패스, 인크. 신경퇴행성 질환의 진단 및 치료 방법
WO2025231343A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases
WO2025240435A1 (en) * 2024-05-14 2025-11-20 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811363A (zh) * 2016-07-01 2018-04-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
SI1720909T1 (sl) 2004-02-23 2012-01-31 Lilly Co Eli Anti-abeta protitelo
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN107289872A (zh) 2017-06-28 2017-10-24 京东方科技集团股份有限公司 测高装置
KR102905634B1 (ko) 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811363A (zh) * 2016-07-01 2018-04-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
AU2022206461A1 (en) 2023-06-29
ZA202306180B (en) 2025-02-26
PE20231748A1 (es) 2023-11-06
TW202243690A (zh) 2022-11-16
IL304072A (en) 2023-08-01
MX2023008196A (es) 2023-07-18
KR20260047659A (ko) 2026-04-08
CA3204444A1 (en) 2022-07-14
WO2022150735A1 (en) 2022-07-14
KR20230130695A (ko) 2023-09-12
EP4274611A1 (en) 2023-11-15
CO2023009089A2 (es) 2023-09-29
KR102942744B1 (ko) 2026-03-23
JP7676556B2 (ja) 2025-05-14
CL2023001992A1 (es) 2024-02-02
US20240010713A1 (en) 2024-01-11
JP2025131566A (ja) 2025-09-09
JP2024503025A (ja) 2024-01-24
AU2022206461B2 (en) 2026-02-05
ECSP23051813A (es) 2023-08-31

Similar Documents

Publication Publication Date Title
TWI843040B (zh) 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 抗類澱粉β抗體及其用途
CN108473566A (zh) 抗N3pGlu淀粉样蛋白β肽抗体及其用途
TW202339794A (zh) 使用ｐ—ｔａｕ１８１水平之治療方法
JP2023539047A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
CN116916957A (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
EP4305060A2 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
CN116981690A (zh) 抗-淀粉样蛋白β抗体及其用途
EA052116B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и варианты их применения
WO2022251048A1 (en) Anti-amyloid beta antibodies and uses thereof
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
KR20180108832A (ko) 조합 요법
JP2023075242A (ja) 再発型の多発性硬化症を治療するための方法
CN117279938A (zh) 抗-N3pGlu淀粉样蛋白β抗体及其用途
HK1150964A (en) Immunotherapy regimes dependent on apoe status